CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) has taken a significant step forward in the fight against Glioblastoma Multiforme (GBM), one of the most aggressive and challenging forms of brain cancer, by releasing a Virtual Investor KOL Connect segment. This segment featured insights from Dr. Erin Dunbar, a leading figure in neuro-oncology and the Director of Neuro-Oncology […]